The last decade has seen Advanced Medicines Manufacturing (AMM) progress from isolated product developments to the creation of industry-academic centres of excellence, regulatory innovation progressing leading to new standards, and product commercialisation across multiple product formats. This paper examines these developments focusing on successful applications and strategies presented at the 2023 Symposium of the International Consortium for Advanced Medicines Manufacturing (ICAMM). Despite these exemplar applications, there remain significant challenges to the sector-wide adoption of AMM technologies.
View Article and Find Full Text PDFTechnology innovations present an opportunity for the agricultural sector to leverage in-field data and inform resource-demanding operations to ultimately promote Sustainable Development Goals (SDGs). The need for data-driven innovations in farming is particularly pertinent to resource-scarce regions, such as the Indian Punjab, where an amalgam of obscure policies and lack of real-time visibility of crops typically leads to the excessive use of farming inputs like freshwater. To this end, this research investigates the use of Internet of Things (IoT) implementations to cultivate (a high-value citrus fruit) for assessing the impact of data-informed irrigation practices on the appropriation of natural sources, farming operations efficiency, and the well-being of smallholder farmers.
View Article and Find Full Text PDFCompeting and coexisting policies (CACPs) may arise from the incompatibility of incentives, standards, and regulatory models between a local state and a federal government, or between two government jurisdictions across which supply networks operate. Traditional studies of supply chain dynamics typically explore the impact of policy regimens as standalone instruments. This study explores how the interplay between CACP regimens can affect the supply dynamics between producers, customers, and their intermediaries.
View Article and Find Full Text PDFThis paper examines the opportunities and challenges facing the pharmaceutical industry in moving to a primarily "continuous processing"-based supply chain. The current predominantly "large batch" and centralized manufacturing system designed for the "blockbuster" drug has driven a slow-paced, inventory heavy operating model that is increasingly regarded as inflexible and unsustainable. Indeed, new markets and the rapidly evolving technology landscape will drive more product variety, shorter product life-cycles, and smaller drug volumes, which will exacerbate an already unsustainable economic model.
View Article and Find Full Text PDFThis paper examines the opportunities and challenges facing the pharmaceutical industry in moving to a primarily "continuous processing"-based supply chain. The current predominantly "large batch" and centralized manufacturing system designed for the "blockbuster" drug has driven a slow-paced, inventory heavy operating model that is increasingly regarded as inflexible and unsustainable. Indeed, new markets and the rapidly evolving technology landscape will drive more product variety, shorter product life-cycles, and smaller drug volumes, which will exacerbate an already unsustainable economic model.
View Article and Find Full Text PDF